Details for New Drug Application (NDA): 205421
✉ Email this page to a colleague
The generic ingredient in FEBUXOSTAT is febuxostat. There are twenty-six drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the febuxostat profile page.
Summary for 205421
| Tradename: | FEBUXOSTAT |
| Applicant: | Alembic |
| Ingredient: | febuxostat |
| Patents: | 0 |
Pharmacology for NDA: 205421
| Mechanism of Action | Xanthine Oxidase Inhibitors |
Medical Subject Heading (MeSH) Categories for 205421
Suppliers and Packaging for NDA: 205421
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| FEBUXOSTAT | febuxostat | TABLET;ORAL | 205421 | ANDA | Alembic Pharmaceuticals Limited | 46708-190 | 46708-190-08 | 80 TABLET, COATED in 1 CARTON (46708-190-08) |
| FEBUXOSTAT | febuxostat | TABLET;ORAL | 205421 | ANDA | Alembic Pharmaceuticals Limited | 46708-190 | 46708-190-10 | 100 TABLET, COATED in 1 CARTON (46708-190-10) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 40MG | ||||
| Approval Date: | Jul 1, 2019 | TE: | AB | RLD: | No | ||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 80MG | ||||
| Approval Date: | Jul 1, 2019 | TE: | AB | RLD: | No | ||||
Complete Access Available with Subscription
